Brief: Resverlogix updates On Apabetalone (RVX-208) study
11/08/2016 12:00
Aug 11 (Reuters) - Resverlogix Corp RVX.TO
* Resverlogix announces positive recommendation from data
safety monitoring board for phase 3 study of Apabetalone
(RVX-208)
* Data review by independent data safety monitoring board
resulted in verbal recommendation for trial to continue as
planned
Source text for Eikon: ID:nCNWjzlBpa
Further company coverage: RVX.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment